Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q1 2019 · 10-Q
Revenue$6.01M$6.01M+25.0% vs Q1 2018 Net Income-$3.33M-$3.33MN/M vs Q1 2018 EPS Diluted-$0.94-$0.94N/M vs Q1 2018 Gross Profit$3,388,000+52.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flow-$2,960,000N/M Free Cash Flowderived-$2,972,000N/M Margins · derivedGross margin56.4%+10.0 pt vs Q1 2018
Operating margin-53.0%+14.6 pt vs Q1 2018
Net margin-55.3%+12.8 pt vs Q1 2018
ended Mar 31, 2019 · filed May 14, 2019 · 44 d after period end